Lung Adenocarcinoma Model
Lung Adenocarcinoma Model - Related Videos
04:36
Adenocarcinoma Engraftment: A Method to Implant Cancer Cells into the Murine Lungs
0 Views •
2023
This video describes a method to engraft lung adenocarcinoma cells in murine lungs by preconditioning the airways with fibrosis-inducing agent–bleomycin. This method significantly enhances orthotopic engraftment of lung cancer cells into murine...
05:49
Establishment of an Ex Vivo Lung Perfusion Rat Model for Translational Insights in Lung Transplantation
0 Views •
Cited by 5 •
2023
Here, we describe the necessary steps for establishing a rat EVLP model and show the inflammatory profile associated with the perfused lungs. The aim is to propagate knowledge and experiences about the rat EVLP model, enabling the integral understanding of the biological responses associated with that revolutionary technique.
08:59
Method of Isolated Ex Vivo Lung Perfusion in a Rat Model: Lessons Learned from Developing a Rat EVLP Program
0 Views •
Cited by 27 •
2015
Ex-Vivo Lung Perfusion (EVLP) has allowed lung transplantation in humans to become more readily available by enabling the ability to assess organs and expand the donor pool. Here, we describe the development of a rat EVLP program and refinements that allow for a reproducible model for future expansion.
09:22
Mouse Pneumonectomy Model of Compensatory Lung Growth
0 Views •
Cited by 14 •
2014
Mouse pneumonectomy is a commonly employed model of compensatory lung growth. This procedure can be used in conjunction with lineage tracing or transgenic mouse models to elucidate underlying mechanisms.
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
0 Views •
2025
This protocol describes the development of a neonatal piglet model of acute lung injury that models early pathogenic events occurring in the preterm lung, including sub-adequate surfactant quantity, hyperoxia, high-pressure ventilation, and inflammation, to facilitate understanding of molecular triggers of bronchopulmonary dysplasia and enhance therapeutic translation.
FAQs
Genetic alterations provide a connection between molecular changes and observable tumor behavior. A suitable model can help researchers examine how disease-associated changes relate to tumor development, progression, or treatment response. Comparing models with different alterations may reveal which biological features influence outcomes and which findings could support biomarker discovery or targeted treatment research.
Tumor-associated cellular interactions and surrounding microenvironmental conditions can affect how lung adenocarcinoma develops and responds to treatment. Models that reproduce some of these features allow investigators to study cancer behavior in a controlled setting rather than focusing only on isolated tumor cells. This context can improve interpretation of therapeutic responses and disease mechanisms.
Cancer cell lines, patient-derived tissue, organoids, and animals each reproduce different aspects of lung adenocarcinoma biology. Cell-based systems can support controlled molecular studies, while patient-derived or organoid systems can preserve selected features of individual tumors. Animal models add organism-level context. Using complementary systems can connect mechanistic observations with treatment-response findings.
Model relevance depends on how well it represents the tumor’s genetic alterations, cellular interactions, and microenvironmental conditions. The intended question also matters: a system useful for studying oncogenic mechanisms may differ from one selected for drug screening or immune-based therapy evaluation. Matching model characteristics to the research objective helps prevent overinterpreting results.
Researchers first select a model system that fits the biological or therapeutic question, then examine tumor development, progression, or treatment response under controlled conditions. Measurements are interpreted in relation to the model’s reproduced genetic, cellular, and microenvironmental features. Results can then inform biomarker studies, treatment comparisons, or follow-up investigations using complementary systems.
These models are used when investigators need to connect molecular features with tumor behavior or therapeutic outcomes. They support drug screening, evaluation of targeted therapies, assessment of immune-based approaches, and identification of biomarkers associated with disease or response. Their controlled experimental setting enables systematic comparisons before findings are considered for broader medical research.
By linking tumor-associated genetic alterations and biological behavior with treatment responses, lung adenocarcinoma models can help investigate why therapies produce different outcomes. Patient-derived tissue and organoid approaches may provide context for individual tumor features, while other systems clarify mechanisms. Together, these findings support research aimed at tailoring treatment decisions to disease biology.